-$0.28 (-0.63%) As of 5:39 PM UTC today

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell REGENXBIO and other ETFs, options, and stocks.

About RGNX

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors; and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381.

Kenneth T. Mills
Rockville, Maryland

RGNX Key Statistics

Market Cap
Price-Earnings Ratio
Dividend Yield
Average Volume
High Today
Low Today
Open Price
52 Week High
52 Week Low


BenzingaSep 15

Looking Into Regenxbio's Return On Capital Employed

Regenxbio (NASDAQ:RGNX) brought in sales totaling $22.04 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 18.58%, resul
BenzingaSep 13

Why Regenxbio Shares Are Trading Higher Today

Regenxbio Inc (NASDAQ: RGNX) is trading significantly higher Monday after the company, and AbbVie Inc (NYSE: ABBV), announced an eye care collaboration. The co
MarketWatchSep 13

AbbVie's deal to develop Regenxbio's investigational gene therapy could be worth $1.8 billion

Shares of AbbVie Inc. ABBV, -0.55% were up 0.8% in premarket trading on Monday after the drug maker announced a potential billion-dollar deal to develop and com

RGNX Earnings

Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
— per share
Expected Nov 3, After Hours

More RGNX News

ReutersSep 13

UPDATE 1-AbbVie, Regenxbio enter deal to develop retinal disease therapy

(Adds details of deal) Sept 13 (Reuters) - AbbVie and Regenxbio Inc entered a partnership to develop and commercialize RGX-314, a gene therapy candidate for th
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure